The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer
Open accessAbstract
Purpose: Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features and clinical features differ in patients with and without BRCA mutations. Patients and Methods: Tumor pathologic features and clinical characteristics were examined in 491 women with breast cancer who underwent genetic testing for BRCA mutations between 1997 and 2006. A retrospective review of medical records was conducted to determine clinical characteristics including ethnicity, age and clinical stage at diagnosis, age at parity, number of full-term pregnancies, use of oral contraceptives and hormone replacement therapy, and BRCA mutation status. Tumor pathology was reviewed to determine histologic type, tumor grade, and estrogen receptor, progesterone receptor, and HER-2/neu status. Results: Of the 491 patients with identified breast cancers, 391 patients were BRCA negative, and 86 patients were BRCA positive. Triple-negative breast cancer (ie, those with negative estrogen receptor, progesterone receptor, and HER-2/neu status) was diagnosed in 57.1% of the BRCA1-positive patients, 23.3% of the BRCA2-positive patients, and 13.8% of the BRCA-negative patients. BRCA1 mutation carriers had higher nuclear grade tumors than the other two groups (P < .001). Of the triple-negative cancer patients, BRCA2 mutation carriers were older when diagnosed than BRCA1 mutation carriers and noncarriers (P < .01). Conclusion: These results suggest that tumors associated with BRCA1 mutations may be divided into two distinct groups, triple-negative and non–triple-negative groups. Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“believed to consist of tumors that do not express ER, progesterone receptor (PR), or HER-2/neu (ie, triple-negative tumors).(8) Several studies have demonstrated that BRCA1-mutation carriers are more likely to be diagnosed with triple-negative breast cancer than noncarriers.”
BackgroundGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · cited 1×
“It is estimated that women with BRCA1 and BRCA2 mutations have a lifetime risk of developing breast cancer as high as 87%.(1,2) However, evidence indicating whether overall prognosis is poorer for women who have BRCA-related cancers has not been conclusive.”
BackgroundThe molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., & Lynch, H. T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w · Cited by 454
Foulkes, W. D., Brunet, J.-S., Stefansson, I. M., Straume, O., Chappuis, P. O., Bégin, L. R., Hamel, N., Goffin, J. R., Wong, N., Trudel, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2970 · Cited by 363
Tumour biological features of BRCA1-induced breast and ovarian cancer
Jóhannsson, Ó. T., Idvall, I., Anderson, C., Borg, Å., Barkardóttir, R. B., Egilsson, V., & Olsson, H. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 345
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254 · cited 1×
“However, evidence indicating whether overall prognosis is poorer for women who have BRCA-related cancers has not been conclusive.(3,4) Currently, treatment recommendations for BRCA-related cancers are similar to those for sporadic breast cancers.”
BackgroundLoman, N., Johannsson, O., Bendahl, P.-O., Borg, �., Fern�, M., & Olsson, H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980715)83:2<310::aid-cncr15>3.0.co;2-w · Cited by 184
Musolino, A., Bella, M., Bortesi, B., Michiara, M., Naldi, N., Zanelli, P., Capelletti, M., Pezzuolo, D., Camisa, R., Savi, M., et al. (2007) · Breast · doi:10.1016/j.breast.2006.12.003 · Cited by 132
Discovery and validation of breast cancer subtypes
Kapp, A. V., Jeffrey, S. S., Langerød, A., Børresen‐Dale, A., Han, W., Noh, D., Bukholm, I. R., Nicolau, M. M., Brown, P. O., & Tibshirani, R. J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-231 · Cited by 129
Optimal Selection of Individuals for BRCA Mutation Testing: A Comparison of Available Methods
James, P. A., Doherty, R. J., Harris, M., Mukesh, B. N., Milner, A. D., Young, M., & Scott, C. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9737 · Cited by 120
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data
van der Groep, P., Bouter, A., van der Zanden, R. A., Siccama, I., Menko, F. H., Gille, J. J. P., van Kalken, C. K., van der Wall, E., Verheijen, R. H. M., & van Diest, P. J. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.032151 · Cited by 101
Noguchi, S., Kasugai, T., Miki, Y., Fukutomi, T., Emi, M., & Nomizu, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990515)85:10<2200::aid-cncr14>3.0.co;2-s · Cited by 99
Li, W.-F., Hu, Z., Rao, N., Song, C.-G., Zhang, B., Cao, M., Su, F., Wang, Y.-S., He, P., Di, G., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9708-3 · Cited by 98
Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
Veronesi, A., de Giacomi, C., Magri, M. D., Lombardi, D., Zanetti, M., Scuderi, C., Dolcetti, R., Viel, A., Crivellari, D., Bidoli, E., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-70 · Cited by 89
BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson, M. E., Rajan, P., Rosen, P., Gilewski, T., Hirschaut, Y., Pressman, P., Haas, B. R., Norton, L., & Offit, K. (1998) · PubMed · Cited by 89
Kim, S., Rimm, D. L., Carter, D., Khan, A. J., Parisot, N., Franco, M. A., Bale, A. E., & Haffty, B. G. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09307.x · Cited by 16
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Metadata
- Authors
- Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-09-10
- Volume
- 26
- Issue
- 26
- Pages
- 4282-4288
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166702788
- Cited by
- 604
- References
- 23
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.